Covenant Health Cancer Center
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Covenant Health Cancer Center sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Covenant Health Cancer Center: 4 sponsored US clinical trials, 3 recruiting.
Covenant Health Cancer Center sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Radiation Mucositis, with 1 trials.
Upper-quartile sponsor footprint
Covenant Health Cancer Center sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
NCT06200259
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
NCT06183268
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT06006806
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
NCT05369234
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Where Covenant Health Cancer Center enrollment is open (later-stage tilt)
3 recruiting of 4 indexed (75% open); 1 completed (25%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Radiation Mucositis (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Covenant Health Cancer Center: open-pipeline peers nationwide
Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Covenant Health Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 75% open enrollment (± trial volume)
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
- Amydis · 75% recruiting · 4 trials
Related
What to do with this Covenant Health Cancer Center page
4 registered trials is a research-attention snapshot, not an endorsement of Covenant Health Cancer Center or any single study.
- 3 of Covenant Health Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Radiation Mucositis is the condition Covenant Health Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Radiation Mucositis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Covenant Health Cancer Center pipeline card: 4 registered trials from official public datasets.Report a data error.